Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) enrolled 48 boys with Duchenne muscular dystrophy (4 to <7 years), with outcomes including clinical safety, pharmacokinetics and pharmacodynamic biomarkers. The study design included pharmacodynamic biomarkers in three contexts of use: 1. Secondary outcomes for pharmacodynamic safety (insulin resistance, adrenal suppression, bone turnover); 2. Exploratory outcomes for drug mechanism of action; 3. Exploratory outcomes for expanded pharmacodynamic safety. Vamorolone was safe and well-tolerated through the highest dose tested (6.0 mg/kg/day) and pharmacokinetics of vamorolone were similar to prednisolone. Using pharmacodynamic biomarkers, the study demonstrated improved safety of vamorolone versus glucocorticoids as shown by reduction of insulin resistance, beneficial changes in bone turnover (loss of increased bone resorption and decreased bone formation only at the highest dose level), and a reduction in adrenal suppression. Exploratory biomarkers of pharmacodynamic efficacy showed an anti-inflammatory mechanism of action and a beneficial effect on plasma membrane stability, as demonstrated by a dose-responsive decrease in serum creatine kinase activity. With an array of pre-selected biomarkers in multiple contexts of use, we demonstrate the development of the first dissociative steroid that preserves anti-inflammatory efficacy and decreases steroid-associated safety concerns. Ongoing extension studies offer the potential to bridge exploratory efficacy biomarkers to clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?
le Roux, C., Meeran, K., & Alaghband-Zadeh, J. (2002) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/0004563021901919 · Cited by 77
Cited by
Therapeutic developments for Duchenne muscular dystrophy
Verhaart, I. E. C., & Aartsma-Rus, A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0203-3 · Cited by 377
Smits, A., Annaert, P., Cavallaro, G., De Cock, P. A. J. G., de Wildt, S. N., Kindblom, J. M., Lagler, F. B., Moreno, C., Pokorna, P., Schreuder, M. F., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14958 · Cited by 55
“There is limited progress in knowledge on how growth and development impact PD. 4 To determine the effects of growth and development on PD, the greatest challenge is probably the robust and direct quantification of drug effects.”
BackgroundInfluentialLiu, G., Lipari, P., Mollin, A., Jung, S., Teplova, I., Li, W., Ying, L., More, V., Lennox, W., Yeh, S., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddad173 · Cited by 23
“Further, inhibition of endogenous corticosteroids was corroborated in a Phase 2a study where treatment with vamorolone at 6 mg/kg/day for 2 weeks resulted in adrenal suppression [27].”
BackgroundMethodResultInfluentialBencze, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010362 · Cited by 20
Metadata
- Authors
- Conklin, L. S., Damsker, J. M., Hoffman, E. P., Jusko, W. J., Mavroudis, P. D., Schwartz, B. D., Mengle-Gaw, L. J., Smith, E. C., Mah, J. K., Guglieri, M., Nevo, Y., Kuntz, N., McDonald, C. M., Tulinius, M., Ryan, M. M., Webster, R., Castro, D., Finkel, R. S., Smith, A. L., Morgenroth, L. P., Arrieta, A., Shimony, M., Jaros, M., Shale, P., McCall, J. M., Hathout, Y., Nagaraju, K., van den Anker, J., Ward, L. M., Ahmet, A., Cornish, M. R., & Clemens, P. R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 136
- Pages
- 140-150
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2892018897
- Cited by
- 103
- References
- 1
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.